表皮生长因子受体（EGFR）外显子 20 号插入（EGFR exon20ins）突变一直是非小细胞肺癌（NSCLC）临床治疗的重要挑战。这类突变占 NSCLC 病例的 2%-3%，占所有 EGFR 突变 NSCLC 的 12%[1, 2]，且存在超 100 种亚型[1, ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
值得关注的是，会议现场投票结果同样呼应这一理念：近九成医生认可预防新发脑转的重要性，提示「预防先行」理念已在肺癌领域引起专家们的高度重视。 脑转移：悬于 ALK 阳性 NSCLC 患者之上的「达摩克利斯之剑」 CTC穿越BBB后定植转化为种植肿瘤细胞（DTC），氧化应激状态后幸存的 DTC 会进入休眠期，此时临床影像MRI 无法检测到 DTC，但微转移已悄悄发生。最终，DTC 动态适应脑部微环境变 ...
SYDNEY, Oct. 13 (Xinhua) -- Non-small cell lung cancer (NSCLC), the most common form of lung cancer, was mapped cell-by-cell using spatial biology and artificial intelligence (AI), taking the ...
在晚期非小细胞肺癌（NSCLC）患者中，约2%携带ROS1融合基因突变。作为针对该靶点的首款靶向治疗药物，克唑替尼曾为ROS1融合阳性NSCLC患者带来显著获益， 可实现 16~20 个月的中位无进展生存期（PFS）与约 45 ...
Background Compared with cytotoxic chemotherapy, the efficacy and safety of immune checkpoint inhibitors (ICIs) for patients ...
Clinical Trials Arena on MSN
ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate
"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of breast cancer, colorectal cancer, and NSCLC.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈